Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

849 United States sites

369 India sites

242 United Kingdom sites

167 Canada sites

145 Italy sites

118 Turkey sites

113 Greece sites

102 France sites

97 Spain sites

49 South Africa sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)

This will be an open-label, dose escalating study with a starting dose of 2mg.

Locations

96 United States sites

Age

18 Years - 45 Years

Phase

Phase 1/Phase 2

LEARN MORE
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease

This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance.

Locations

128 United States sites

41 Italy site

36 United Kingdom sites

25 Germany sites

Age

2 Years - 11 Years

Phase

Phase 3

LEARN MORE
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD).

Locations

288 United States sites

96 Italy sites

44 Germany sites

Age

12 Years - 35 Years

Phase

Phase 3

LEARN MORE
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)

This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.

Locations

939 United States sites

Age

> 4 Years

LEARN MORE
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Locations

329 Brazil sites

230 Turkey sites

165 Spain sites

142 United States sites

138 Italy sites

92 France sites

57 United Kingdom sites

Age

12 Years - 55 Years

Phase

Phase 2

LEARN MORE
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models [PREMIER]

This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Locations

171 United States site

Age

18 Years - 65 Years

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult participants with severe sickle cell disease (SCD).

Locations

817 United States sites

135 Canada sites

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)

The purpose of this study is to evaluate crovalimab for the treatment of a sickle cell pain crisis (also known as a VOE) that requires hospitalisation in adult and adolescent participants with SCD.

Locations

179 Spain sites

150 Brazil sites

146 United States sites

100 France sites

88 United Kingdom sites

50 Italy sites

Age

12 Years - 55 Years

Phase

Phase 1

LEARN MORE
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease

The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD).

Locations

306 United States sites

191 United Kingdom site

138 Lebanon sites

132 Greece sites

20 France sites

Age

18 Years - 60 Years

Phase

Phase 2

LEARN MORE